As an endogenous neuroprotectant agent, adenosine is extensively distributed and is particularly abundant in the central nervous system (CNS). Under physiological conditions, the concentration of adenosine is low intra-and extracellularly, but increases significantly in response to stress. The majority of adenosine functions are receptor-mediated, and primarily include the A1, A2A, A2B, and A3 receptors (A1R, A2AR, A2BR, and A3R). Adenosine is currently widely used in the treatment of diseases of the CNS and the cardiovascular systems, and the mechanisms are related to the disease types, disease locations, and the adenosine receptors distribution in the CNS.
| INTRODUC TI ON
Adenosine, short for adenine nucleoside, is chemically known as 6-amino -9-β-d-ribofuranosyladenine, and it is formed by the binding of adenine's N-9 to D-ribose's C-1 via the β-N9-glucoside bond.
Adenosine has strong effects in the coronary artery, and anti-epilepsy, which is often used to treat cerebrovascular disorders, apoplexy sequelae, coronary insufficiency, angina, arteriosclerosis, and primary hypertension. Since energy utilization is ubiquitous, 1 adenosine can be produced both intra-and extracellularly in tissues throughout the body, including the brain and heart. Adenosine is widely distributed in the central nervous system (CNS). Adenosine can be considered as a central excitatory and inhibitory neurotransmitter in the brain. Under ischemia, hypoxia, tissue damage, and other pathologic conditions, the degradation of ATP is increased. As a signaling nucleoside, adenosine plays a protective role by interacting with adenosine receptors when its extracellular concentration is increased. 2 
| ADENOS INE S TRUC TURE AND ITS MODIFIC ATION
Adenosine contains multiple reactive sites of nucleoside molecules and thus has a strong "plasticity." According to the classification of types of modification, modifications can be divided into base modification, glycosyl modification, and simultaneous basic-glycosyl modification, such as the addition of one site, the substitution of two sites, the substitution or elimination reaction of six sites on the base, and the introduction of different groups on the 2′ site of the glycosyl (Figure 1 ). The main introduction sites are 2, 6, and 5′ on the bases and glycosyl in the treatment of central nervous diseases. The modification of two sites in bases is usually a substitution reaction to produce 2-halogen products, such as 2-chloro-adenosine. The six site amino derivatives can be deaminated by deamination or hydrolyzed by HNO 2 diazotization to form hydroxyl substitution derivatives, such as inosine.
2′ site derivatives in glycosyl with protective effects on nerve cells were obtained by conversion, substitution and elimination, such as adenosine cobalt amine. Other derivatives are listed in Table 1 . Because of the rapid uptake and metabolism of adenosine, its balance is inefficient during times of stress. Adenosine does not exceed 1 μmol kg −1 in the brain under normal circumstances.
| ADENOS INE PRODUC TION AND ME TABOLIS M
Intracellular
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However, adenosine degrades at a slower rate than those by which it is produced during ischemia, trauma, inflammation, and some other pathological conditions. This imbalance leads to a rapid increase in extracellular adenosine concentrations. However, adenosine has a short half-life and this concentration change is temporary, and it is difficult to sustain as a protective mechanism against subsequent pathological conditions.
F I G U R E 1
The modifying sites of adenosine. Adenosine derivatives are obtained by base modification, glycosyl modification, and simultaneous modification at multiple reaction sites of adenosine, which have different roles in central nervous system diseases
| ADENOS INE RECEP TOR S
Many physiological functions of adenosine are achieved through receptor mediation. The adenosine receptors belong to the G protein-coupled receptor (GPCR) family. This family mainly includes four kinds of receptors, A1, A2A, A2B, and A3, of which A1R and A3R belong to the Gi family of G proteins while A2AR and A2BR are part of the Gs family.
A1R is a glycoprotein containing 326 amino acids with a relative molecular weight of 36 600. A1R has the highest affinity for adenosine, is coupled with pertussis sensitive G protein (Gi1~3,Go) and exists in all systems 16 . However, the expression of A1R is highest in the CNS, mainly distributed in the cerebral cortex, thalamus, hippocampus, basal forebrain, lateral hypothalamus, medulla oblongata, olfactory bulb and cerebellum, etc. The A1R is activated in the presynaptic membrane and can inhibit the activity of adenylyl cyclase (AC), reduce the content of cyclic adenosine-3,5 monophosphate (cAMP), and regulate cAMP-dependent protein kinase activity. In addition, A1R can also activate phospholipase C (PLC), and the latter can adjust the inositol phosphate metabolism of the cell membrane, increasing the content of inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG). Among these, IP3 can stimulate the release of Ca
2+
from the intracellular calcium store and inhibit the N-, Q-, and P-type calcium channels, which leads to the reduction in Ca 2+ influx, inhibits the release of glutamate, and reduces the excitability of nerve conduction. 1 In the postsynapse membrane, A1R becomes activated to open potassium channels and increase the outflow of K + , resulting in hyperpolarization of the membrane, thus reducing excitability and protecting neurons. 17 In addition, A1R, when activated, can also open the ATP sensitive potassium channel (KATP) of neurons in the substantia nigra, increasing the outward current and decreasing the excitability of the membrane.
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The relative molecular weight of A2AR is 45 000, and it is mainly distributed in the brain areas rich in dopamine, such as the striatum globus pallidus, nucleus accumbens, olfactory tubercle, bulbus olfactorius, and nucleus nervi acustici. A2AR is also expressed in the ce- has different effects at different doses and administration times.
Activation of A3R has both neuroprotective and neurotraumatic effects ( Figure 3 ).
During the pathological circumstances of slight and short-term ischemia, trauma, and inflammation, it is possible to improve the protein expression level of AR and increase the synthesis of receptor proteins; perhaps the membrane "spare receptor" is activated, or the transport of receptor proteins from the cytoplasm to the cell membrane is accelerated. 22 The change in AR is sustained over a long duration of approximately 1-3 or 7 days, during which adenosine is more likely to bind to its receptors that are synthesized by brain cells.
| THE ROLE OF ADENOS INE AND ITS RECEP TOR S IN CENTR AL NERVOUS SYS TEM DISE A SE S

| Adenosine and cerebral ischemia
Cerebral ischemia is a common acute cerebrovascular disease 
| Excitatory amino acid (EAA)
The toxicity of excessive EAAs, such as glutamic acid and aspartate,
is an important cause of neuronal death in cerebral ischemia. By activating A1R, the release of EAA can be inhibited to protect nerve cells, and the mechanism may be as follows: In presynaptic membranes, A1R reduces calcium influx by inhibiting N or Q-type Ca Moreover, the protective effect of selective A2AR antagonists on cerebral ischemia is related to the dose. Low doses of selective A2AR
antagonists have a neuroprotective effect, but the protective effect disappears at an increased dose. The possible reasons are that a high dose of selective A2AR antagonists may block other adenosine receptors, such as A1R, and other possibilities are its peripheral effects on blood pressure reduction, heart rate disruption, and platelet aggregation, which lead to nutrition deficiency in brain injury sites. But its priority to block the A2AR on postsynaptic membranes can inhibit NMDA toxicity thus protect the nerve 26 . Popoli et al 27 think that the selective A2AR antagonist CSC has a neuroprotective effect during the first 15 minutes after cerebral ischemia in rats, but this effect will disappear after 2 weeks of continuous treatment with the same dose of CSC. Thus, the medication duration is another factor influencing the neuroprotective effect of the selective A2AR antagonist.
Therefore, adenosine can inhibit the release of glutamate and aspartate after ischemia and reduce the cytotoxic effects of EAA, thereby protecting neurons.
| Reactive astrogliosis
Reactive astrogliosis is a repair response that is characterized with astrocytes hypertrophy, protuberant elongation, glial fibrillary acidic protein (GFAP) expression and astrocyte proliferation after brain damage. The activation of different adenosine receptors has different effects on reactive gliosis. A1R and A3R have inhibitory effects on reactive gliosis, while A2R promotes glia reactions. A1R can accelerate the apoptosis of RCR-1 astrocytoma in rats, 28 and A3R can also inhibit reactive gliosis by inducing apoptosis of astrocytes. Since the adenosine analogue 2-chloro-adenosine (2-CA) is not sensitive to A1R and A2R antagonists, this may be mediated by A3R through cysteine kinase-3 pathways, or it may be related to the decrease in the concentration ratio between SAH and S-adenosyl methionine (SAM), which triggers apoptosis. 29 A2R may indirectly promote reactive gliosis by interacting with other cytokines, such as tumor necrosis factor-alpha (TNF-α), basic fibroblast growth factor (bFGF).
| Trophic action of nerves
Astrocytes can secrete a large number of neurotrophic factors and cytokines with neuroprotective effects, including nerve growth factor (NGF), S-100B, neurotrophic factor 3 and 4 (NT3 and NT4), brain-derived neurotrophic factor (BDNF) and vascular endothelial growth factor (VEGF), IL-6 and selective chemokines (CCL2). Nerve growth factor plays a neuroprotective role in cerebral ischemia, it is secreted mainly by astrocytes next is microglia, and is related to A1R and A2aR, respectively. As one of the factors in the S-100 family, S-100B is a Ca 2+ binding protein mainly secreted by astrocytes and plays important roles in cell proliferation, differentiation, and protein phosphorylation, which is mediated by adenosine A1R. After binding to its receptor, S-100B can induce NF-κB nuclear translocation, stimulate the expression of Bcl 2, and promote the recovery of neurons and the growth of axons. antagonist has a certain protective effect against AD. In addition,
| Adenosine and Alzheimer's disease
there is an association between isoflurane exposure and spatial memory impairment, and declines in NR2B levels and increases in Aβ and P-tau levels may be achieved by activating A1AR. with a greater hippocampal volume and improved memory. 41 In terms of other receptors, caffeine has a protective effect on the amyloid process by inhibiting the A3R-mediated internalization of the β-amyloid precursor. 42 Thus, the adenosine receptor balance theory has been increasingly accepted in AD.
| Adenosine and depression
Depressed mood is the main clinical symptom of depression disorder. The hypothalamus, as the center of the neuroendocrine system, integrates neuromodulation and humoral regulation, and regulates the human body temperature, food intake, and endocrine activities extensively. Through close contact with the limbic system, the hypothalamus participates in emotional responses. Many studies have reported on depression and adenosine. In 2001, Berk showed that the function of the adenosine A2a receptor was weakened in platelets of patients with depression. In 1999, Elgun found a decline of adenosine deaminase (ADA) activity in the plasma of patients with major depression, and it had a negative correlation with the severity of depression, which indirectly suggested that adenosine may be involved in the pathological changes of major depression. Adenosine receptors also play a role in the balance theory during depression.
Lindquist et al 43 think that adenosine A1R and A2AR are involved in the antidepressant effect of adenosine. Adenosine A2AR is upregulated in the cortex by early febrile seizures, thus inducing depressive behavior in adult rats. 44 It was demonstrated that caffeine, a nonselective A2AR antagonist, can prevent chronic depression caused by excision of the bilateral olfactory bulb. 45 In addition, the adenosine level is negatively correlated with affective disorder and purine is not adequately balanced in these patients. 46 Adenosine and inosine regulate depression-like behavior in adult rodent models, and inosine is the adenosine metabolism product that binds to adenosine receptors and activates the intracellular ERK-CREB signaling pathway. 
| Adenosine and Parkinson's disease
Parkinson's disease (PD) is a common neurodegenerative disease.
The main pathological change is the degeneration and death of dopaminergic (DA) neurons in the substantia nigra of the midbrain, which leads to a significant decrease in the content of DA in the striatum and the occurrence of acidophilic inclusion bodies (Lewy bodies) in the cytoplasm of surviving neurons in the substantia nigra. can alleviate the cognitive impairment of PD. 49 In addition, A2AR
antagonists can also reduce l-dopa induced dyskinesia. 
| Adenosine and epilepsy
Epilepsy is a chronic and recurrent brain dysfunction syndrome that is caused by the abnormal discharge of neurons in the brain. Epilepsy is clinically manifested as a whole body tonic clonus attack, and during the seizure, the EEG shows typical explosive multi-spinous waves, and spine-slow waves. The main pathogenesis is glial cell proliferation, adenosine dysfunction, abnormal nerve conduction pathways, selective neuron cell loss, nerve inflammation, and mossy fiber bud phenomenon.
| Astrocyte
Astrocytes 
| Adenosine steady-state
Adenosine kinase converts adenosine into AMP in astrocytes, and the intracellular adenosine concentration then decreases. 
| Glutamic acid
Glutamate has the highest content of amino acids in the CNS and is one of the explicit EAAs. Glutamate has a wide and strong excitatory effect on the cerebral cortex and is closely related to the triggering and spreading of epileptic discharges. Ca 2+ is an important second messenger, and calcium signaling in astrocytes is mainly controlled by receptors. The release of glutamate is related to adenosine binding to its receptor. When adenosine binds to A1R, it inhibits the release of excitatory transmitter glutamate by inhibiting the Ntype voltage-gated calcium ion channel. When adenosine binds to A2AR, it increases intracellular calcium ion concentration through the protein kinase A pathway, thereby stimulating the release of glutamate. 59 Therefore, activation of adenosine A1R or inhibition of adenosine A2AR can inhibit the release of glutamate.
| Epigenetic modification
Epigenetic modifications include changes in DNA methylation that lead to the change in gene expression. Therefore, there may be a basis of epileptogenesis by inducing permanent changes in neural excitability. 60 The main mechanism is that the methyl group is provided by S-adenosyl-l-methionine(SAMe) and selectively added by cytosine of C and G nucleotides of DNA under the catalysis of DNA methyltransferase(DNMTs), and s-adenosine homocysteine (SAH) produces adenosine and homocysteine by hydrolytic enzyme. 61 Therefore, adenosine can inhibit or reverse these changes, such as adenosine not being cleared in time from the synaptic cleft, and the treatment of exogenous adenosine can inhibit the process of DNA methylation and thus inhibit the occurrence of epilepsy. The epigenetic function of endogenous adenosine was determined by inducing DNA hypomethylation due to biochemical interference into the methylation pathway. 62 Exogenous adenosine can reverse the DNA methylation process in temporal lobe epilepsy of rats, inhibit the mossy fiber sprouting in the hippocampus, and control the occurrence of epilepsy.
| Gamma-aminobutyric acid receptor
GABA is an important inhibitory neurotransmitter in the CNS. Its 
| Adenosine and sleep disorders
The "sleep substance," adenosine, is an effective endogenous sleeppromoting factor which accumulates in the brain during wakefulness and induces physiological sleep. 65 Among the four adenosine receptors, the role of A2AR is predominant in sleep regulation, whereas A1R contributes to sleep induction in a region-dependent manner but may not be absolutely necessary for sleep homeostasis. 66 In nor- which plays a role in cortical arousal. 67 In addition, adenosine can also activate GABA neurons by reducing GABA inputs in the ventrolateral preoptic nucleus (VLPO) for sleep induction, and inhibit glutamate neurons in cerebral cortex, striatum, hippocampus, and other brain regions to achieve the coordination between different sleep behaviors. 68 
| ADENOS INE TRE ATMENT
Manipulation of endogenous adenosine level is used in the treatment of CNS disorders. For example, adenosine A1R agonists or ADK inhibition can effectively prevent or reduce the onset of CNS diseases.
However, exogenous adenosine therapy is not the main treatment method, 69 due to the side effects of adenosine in the cardiovascular system and the hepatotoxicity of ADK inhibitors, as well as the fact that exogenous adenosine is quickly absorbed and metabolized after entering the human body by the high affinity nucleoside transporters located on red blood cells, capillary endothelial cells, and smooth muscle cells. 70 However, the ultimate goal of these approaches is to
The mechanism of action of adenosine in epilepsy. Adenosine therapy for epilepsy was summarized from the aspects of astrocytes, ADK induced the changes of adenosine concentration, changes in DNA methylation, GABAAR increase local adenosine levels in the brain while avoiding side effects and damage to other organs. Therefore, adenosine metabolic balance has become the developmental direction of adenosine synergistic therapy in brain.
| Silk that controls adenosine release
The continuous release of adenosine can be controlled by planting silk membranes wrapped with adenosine around the hippocampus, which can effectively control the onset of epilepsy. 71 
| ADK expression control
Adenosine can be released from human mesenchymal stem cells and mouse embryonic stem cells with endogenous ADK gene knocked out after being implanted into the hippocampus. 72 Theofilas used an adenovirus eight gene expression system to knock out the ADK gene, the ADK level of glial cells in the hippocampus decreased, and the occurrence of epilepsy was controlled. 
| Adenosine receptors
When the adenosine A1R gene was knocked out in mice, a ketogenic diet could not exert effects on epilepsy, indicating that a ketogenic diet inhibited the generation of epilepsy through the excitatory effect of adenosine A1R. 74 Yang et al 75 also demonstrated that a ketogenic diet significantly increased the tolerance to cerebral ischemia in mice, which may be achieved by increasing the level of extracellular adenosine in the ischemic area and may be mediated by A1 receptors. Researchers also found that the c-fos immune response activity in KO mice was higher than in WT mice by knocking out adenosine A2A receptors in the anterior cingulate and amygdala, thus causing defects in social active behavior (social withdrawal), such as in autism and depression. 76 
| Trophic action of nerve
As a metabolite of adenosine, inosine can promote axonal regeneration, mainly by activating intracellular serine/threonine kinases, thus upregulating the key factor GAP-43 protein required for axonal regrowth and acting as a neural growth factor. 77 
| Improve blood rheology
After the knockout of the A2AR gene in mice, platelet aggregation was enhanced. Therefore, the activation of A2AR could improve haemorheology, inhibit platelet aggregation, and promote thrombolysis. 78 
| Excitatory cytotoxicity and Ca
2+ alleviation
Low and medium concentrations of adenosine can activate adenosine A1R and inhibit the release of glutamate. Medium and high concentrations of adenosine can activate adenosine A2AR and promote the release of glutamate. Adenosine A2AR has an inhibitory effect on A1R at medium and high concentrations, and the inhibitory effect increases with concentration. 79 
| S IDE EFFEC TS OF ADENOS INE
Adenosine has a few side effects. The most common side effects are flushing, discomfort in the throat, neck, jaw, upper limbs and gastrointestinal tract, breathing difficulties, and dizziness. Because adenosine has a very short half-life, these side effects usually do not require intervention and disappear quickly, which are easily accepted by patients. Adenosine is applicable to patients who cannot exercise for various reasons or cannot achieve the target amount of exercise.
| D ISCUSS I ON
In However, the concentration of adenosine is only temporarily elevated and is quickly metabolized. At the same time, a high concentration of adenosine activates A2AR, and the concentration of EAA also rises sharply, initiating a series of pathophysiological processes that eventually lead to the necrosis or apoptosis of nerve cells.
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As low concentrations of adenosine can activate A1R and inhibit the release of EAAs, A2AR is conversely activated with an increase in adenosine concentration, and A2AR can block heteromeric A1R through a receptor-receptor allosteric trans-inhibition. 79 Therefore, adenosine A2AR antagonists are very important for the protection of the CNS.
In the pathological conditions of ischemia, hypoxia, trauma, and inflammation, the extracellular adenosine concentration increases rapidly, resulting in an imbalance of intracellular and extracellular concentrations of adenosine. Adenosine has a short half-life, adenosine concentration is difficult to sustain the protective effect during pathological conditions. There are many ways to manipulate the endogenous adenosine concentration including adenosine agonists administration, ADK, ADA and extracellular enzymes (such as CD39 and CD73) regulation and the use of dipyridamole to inhibit the adenosine transporter. 84 Exogenous adenosine can also be used to increase the adenosine concentration, 85 Yuan et al 86 found
that the effect of preconditioning with adenosine on brain ischemic tolerance in rats. Perrier et al 87 think that the main effects of adenosine were to decrease neurotransmitter release probability and to attenuate short-term depression mechanisms. But this use is relatively rare, and it needs to be further examined. At the same time, whether adenosine receptor balance or intracellular and extracellular adenosine concentration balance has a key role in the treatment of CNS diseases remains unclear. The specific mechanisms remain to be further studied. 
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